HOME >> MEDICINE >> NEWS
Aluminum foil lamps outshine incandescent lights

CHAMPAIGN, Ill. -- Researchers at the University of Illinois are developing panels of microcavity plasma lamps that may soon brighten peoples lives. The thin, lightweight panels could be used for residential and commercial lighting, and for certain types of biomedical applications.

Built of aluminum foil, sapphire and small amounts of gas, the panels are less than 1 millimeter thick, and can hang on a wall like picture frames, said Gary Eden, a professor of electrical and computer engineering at the U. of I., and corresponding author of a paper describing the microcavity plasma lamps in the June issue of the Journal of Physics D: Applied Physics.

Like conventional fluorescent lights, microcavity plasma lamps are glow-discharges in which atoms of a gas are excited by electrons and radiate light. Unlike fluorescent lights, however, microcavity plasma lamps produce the plasma in microscopic pockets and require no ballast, reflector or heavy metal housing. The panels are lighter, brighter and more efficient than incandescent lights and are expected, with further engineering, to approach or surpass the efficiency of fluorescent lighting.

The plasma panels are also six times thinner than panels composed of light-emitting diodes, said Eden, who also is a researcher at the universitys Coordinated Science Laboratory and the Micro and Nanotechnology Laboratory.

A plasma panel consists of a sandwich of two sheets of aluminum foil separated by a thin dielectric layer of clear aluminum oxide (sapphire). At the heart of each lamp is a small cavity, which penetrates the upper sheet of aluminum foil and the sapphire.

Each lamp is approximately the diameter of a human hair, said visiting research scientist Sung-Jin Park, lead author of the paper. We can pack an array of more than 250,000 lamps into a single panel.

Completing the panel assembly is a glass window 500 microns (0.5 millimeters) thick. The windows inner surface is coated with a phosphor f
'"/>

Contact: James E. Kloeppel
kloeppel@uiuc.edu
217-244-1073
University of Illinois at Urbana-Champaign
4-Jun-2007


Page: 1 2

Related medicine news :

1. Aspirin use during pregnancy could reduce risk of pre-eclampsia
2. Improvement seen in fetal survival following preeclampsia
3. When preventing pre-eclampsia, a little carbon monoxide goes a long way
4. Vitamin C and E supplements do not prevent pre-eclampsia in pregnant women at risk
5. Highlights from the August 2007 Journal of the American Dietetic Association
6. Highlights from the June 2007 Journal of the American Dietetic Association
7. Research highlights from Thoracic Society Conference
8. SCAI highlights study using wireless technology to speed care of heart attack patients
9. SCAI Founders Lecture highlights remarkable progress in catheter-based aortic valve replacement
10. Highlights from the May 2007 Journal of the American Dietetic Association
11. Other highlights in the May 2 JNCI

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Aluminum foil lamps outshine incandescent lights

(Date:5/21/2013)... 21, 2013 Heritage Woods of Dwight ... affordable assisted living community, is hosting a Quality Home Health ... 2 p.m. on Tuesday, May 28. , The community, which ... older adults of all incomes, including those on Medicaid, who ... program is open to the public. There is no ...
(Date:5/21/2013)... the George Washington (GW) University School of ... the launch of the Avance Center for ... between SPHHS, the Maryland Multicultural Youth Centers, ... This university-community partnership aims to address public ... through research, mutual capacity building and prevention ...
(Date:5/21/2013)... 2013 Patients of Dr. Michael Shenk and ... teeth due to gum disease and would like permanent tooth ... treatment with laser gum surgery. Gum disease must ... success rate out of all tooth replacement options. , ... new procedure cleared by the Food and Drug Administration (FDA) ...
(Date:5/21/2013)... LEAWOOD, Kan. Primary care practice transformation on ... health care reform efforts aimed at achieving better ... Amid emerging evidence that transformation toward the patient-centered ... today,s health care environment, the U.S. Department of ... and Quality funded 14 studies to learn more ...
(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker ... the rights of victims injured by defective medical devices, ... Bone & Joint Surgery on May 15, 2013. The ... used to identify complications that occur in patients with ... of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , ...
Breaking Medicine News(10 mins):Health News:Heritage Woods of Dwight Affordable Assisted Living to Host Informational Program on the Do's and Don'ts of Arthritis 2Health News:GW launches center to address health disparities in the Latino immigrant community 2Health News:GW launches center to address health disparities in the Latino immigrant community 3Health News:Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 3Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 4Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 5Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 6Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3
(Date:5/21/2013)... , May 21, 2013  Vasomedical, Inc. (OTC BB: ... the design, manufacture and sale of medical devices and in ... Dr. Jun Ma , President and CEO ... LLP MicroCap Conference on Thursday, May 30, 2013 in ... Hotel. The Company,s presentation is scheduled to ...
(Date:5/21/2013)... 21, 2013 Reportlinker.com announces that ... in its catalogue:   ... Optical Coherence Tomography (OCT) ... OBJECTIVES   BCC,s ... offer synopsis of the current and future ...
(Date:5/21/2013)... Fla. , May 21, 2013  Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...
Breaking Medicine Technology:Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
Cached News: